DISCLAIMER — Not financial advice. Educational content only, not an offer or solicitation to buy or sell any security. Biotech and small/mid-cap stocks are highly speculative and volatile and can result in a partial or total loss of capital. Do your own research and consult a licensed advisor where appropriate. / Contenuti a solo scopo informativo e didattico, non costituiscono consulenza finanziaria né offerta o sollecitazione al pubblico risparmio ai sensi delle normative CONSOB e SEC. Le azioni biotech e le small/mid cap sono strumenti altamente speculativi e volatili e possono comportare la perdita parziale o totale del capitale investito. Si raccomanda di effettuare sempre le proprie ricerche e, se necessario, di rivolgersi a un consulente abilitato.
Merlintrader Trading Pub
Biotech catalyst news and analysis. FDA PDUFA tracker
Merlintrader Trading Pub
Biotech catalyst news and analysis. FDA PDUFA tracker
Co-Diagnostics, Inc.
Molecular Diagnostics | PCR Testing | Tuberculosis Detection | Arabia Saudita JV | AI Turnaround Play
$0.37
52W High: $1.53 | Low: $0.12
Market Data (Nov 28, 2025): Market Cap: $12.78M | Avg Volume: 772.9K | P/S: 44.48 | EPS: -$0.16 (Q3 2025)
Financial Health: Cash: $11.4M | Recent RDO: +$10.8M | Total Liquidity: ~$22M | Burn Rate: ~$2.5M/month | Runway: ~9 months
Financial Health: Cash: $11.4M | Recent RDO: +$10.8M | Total Liquidity: ~$22M | Burn Rate: ~$2.5M/month | Runway: ~9 months
Last Updated: November 28, 2025 | SEC Verified | All data sources cited
? Company Overview
Co-Diagnostics, Inc. (NASDAQ: CODX) is a molecular diagnostics company specializing in the development, manufacturing, and commercialization of rapid PCR diagnostic tests. Core focus: affordable, rapid tuberculosis (TB) detection tests for global markets (MENA, Africa, Asia). Company historically revenue-focused but currently in severe financial distress with strategic pivots toward AI and international partnerships.
⚠️ CRITICAL SITUATION – Q3 2025 REVENUE COLLAPSE
- Q3 2025 Revenue: $145,380 – down 77% YoY from $641,141 Q3 2024
- 9-Month 2025 Revenue: ~$510K estimated
- Q3 2025 Net Loss: -$5,886,823 (-$0.16 per share)
- Q3 Operating Loss: -$7,013,848
- 9-Month 2025 Operating Expenses: $23.9M
- Monthly Burn Rate: ~$2.5M/month (average 9M burn)
- Runway (Pre-RDO): ~4.5 months with $11.4M cash
- Nov 2025 Registered Direct Offering (RDO): +$10.8M additional liquidity (total ~$22M)
- Runway (Post-RDO): ~9 months (~1 year) with $22M available
✅ Verified against: SEC 10-Q Q3 2025 | NASDAQ Press Release (Nov 12, 2025) | StockTitan analysis | Finviz (Nov 28)
? Q3 2025 Financial Results (SEC VERIFIED)
| Metric | Q3 2025 | Q3 2024 | Change |
|---|---|---|---|
| Total Revenues | $145,380 | $641,141 | -77% |
| Cost of Revenues | $26,285 | $297,403 | -91% |
| Gross Profit | $119,095 | $343,738 | -65% |
| Gross Profit Margin | 82% | 54% | +28 pts |
| Sales & Marketing | $568,937 | $1,059,745 | -46% |
| General & Administrative | $1,815,945 | $4,287,380 | -58% |
| Research & Development | $4,480,678 | $4,880,315 | -8% |
| Depreciation & Amortization | $267,383 | $351,235 | -24% |
| Total Operating Expenses | $7,132,943 | $10,578,675 | -33% Improved |
| Operating Loss | -$7,013,848 | -$10,234,937 | -31% Improved |
| Net Loss | -$5,886,823 | -$9,696,455 | -39% Improved |
| Diluted EPS | -$0.16 | -$0.32 | -50% Improved |
✅ Source: SEC 10-Q (StockTitan Q3 2025 detailed breakdown) | NASDAQ Press Release ↗ | PRNewswire ↗
9-Month 2025 (Jan-Sep) – SEC CIK 1378325
| Metric | 9M 2025 | 9M 2024 | Change |
|---|---|---|---|
| Total Revenues | ~$510K | ~$3.7M | -86% |
| Operating Expenses (9M) | $23.9M | $31.2M | -23% |
| Monthly Average Burn | $2.66M/month | $3.47M/month | -23% |
| Net Loss (9M) | -$32.18M | -$31.2M | +3% Worse |
| Earnings Per Share (9M) | -$0.53 | -$0.85 | -38% Improved |
Balance Sheet & Liquidity (September 30, 2025)
| Item | Sept 30, 2025 | Dec 31, 2024 | Change |
|---|---|---|---|
| Cash & Equivalents | $6.8M | $9.2M | -26% |
| Marketable Securities | $4.6M | $5.1M | -10% |
| Total Pre-RDO Liquidity | $11.4M | $14.3M | -20% |
| Q3 2025 RDO Proceeds | $3.8M | — | NEW |
| Post-Q3 RDO Proceeds (Oct-Nov) | $7.0M | — | NEW |
| Total Available Liquidity (Nov 2025) | ~$22.2M | — | +$10.8M added |
| Accumulated Deficit | -$162.3M | -$130.2M | -$32.1M |
| Book Value Per Share | $0.83 | $1.16 | -28% |
✅ Cash Sept 30: SEC CIK 1378325 10-Q | RDO Proceeds: Q3 RDO ($3.8M) ↗ + Subsequent RDO ($7.0M)
⏰ CRITICAL CASH RUNWAY CALCULATIONS
| Scenario | Available Cash | Monthly Burn | Runway | Status |
|---|---|---|---|---|
| Pre-RDO (Sep 30) | $11.4M | $2.66M | 4.3 months | ? CRITICAL |
| Post-RDO (Nov 2025) | $22.2M | $2.66M | 8.3 months (~9 months) | ⚠️ TIGHT |
| Conservative (High Burn) | $22.2M | $3.0M | 7.4 months | ⚠️ TIGHT |
? URGENT: Arabia Saudita JV MUST Deliver Revenue by H2 2026
WITHOUT new revenue from Arabia JV or AI Primo platform by mid-2026, company faces critical capital raise or bankruptcy scenario. The $22.2M liquidity extends runway only to ~Q2-Q3 2026 at current burn rates. Additional dilutive capital raises are highly likely if strategic initiatives fail to generate revenue.
? Strategic Partnerships & Catalysts
?? Arabia Saudita Joint Venture – CoMira Diagnostics
- Partner: Saudi-based diagnostic distribution entity
- Focus Products: TB detection, multiplex respiratory testing (influenza, RSV, COVID, rhinovirus)
- Market Opportunity: MENA/North Africa TB diagnostics market (endemic TB prevalence)
- Revenue Timeline: H1-H2 2026 (critical for survival)
- Risk: Execution on JV commercialization; partner performance; market adoption
? Primo AI Platform – Strategic Pivot
- Business Model: AI-powered diagnostic decision support SaaS
- Status: Early-stage development; beta testing planned 2026
- Revenue Potential: Cloud licensing to diagnostic labs (2027 estimated)
- Risk: Competitive cloud diagnostics market; adoption uncertain; revenue timing too late for current cash crisis
? Other Programs
- MTB POC Instrument: NIH-supported TB point-of-care test (regulatory registration ongoing)
- Multiplex Respiratory Panel: Clinical trials for rapid testing kit (2025-2026)
- CoSara SPAC / Indian JV: Potential strategic alternative being explored
? CEO & Management
Dwight Egan – Chief Executive Officer & Founder
Background: Founded Co-Diagnostics in 2014; led COVID-era PCR boom (2020-2021). Now navigating post-pandemic revenue cliff with strategic refocus on emerging markets TB diagnostics, international JVs (Arabia Saudita CoMira, Indian CoSara), and AI platform development.
Recent Quote (Nov 2025): “We are entering one of the most active and strategically important periods in our Company’s history.”
? Strategic Timeline & Catalysts
November 2025 (NOW)
Registered Direct Offering (RDO) Closed – Total $10.8M capital raise extends runway from 4.3 months to ~9 months. Total available liquidity now $22.2M
Q4 2025
Critical Window: No revenue momentum. Company must demonstrate CoMira JV progress and Primo AI development to prevent stock collapse and negative sentiment.
H1 2026 (CRITICAL)
CoMira JV Launch – SURVIVAL DEPENDENT – Arabia Saudita partnership must begin MENA distribution. First revenue recognition essential to extend runway beyond Q2 2026.
H2 2026
MTB POC Instrument Progress – NIH-supported TB test regulatory milestones; multiplex respiratory panel clinical trial updates
2027
Primo AI Platform Revenue Beta – Cloud SaaS licensing begins IF adoption achieved among diagnostic labs
? Bull vs Bear Case
? BULL CASE (Extreme Risk)
- Arabia JV CoMira begins REVENUE generation in H1-H2 2026 → inflection point
- TB/respiratory diagnostics market MENA = multi-$100M TAM
- Book value $0.83 vs stock $0.37 = 124% potential upside to book value
- RDO (+$10.8M) extends runway to ~9 months (buys execution time)
- NIH support for MTB POC increases FDA approval probability
- CoSara Indian JV potential SPAC alternative value unlock
- Stock down 76% from highs = sentiment compression (some bargain hunters)
- Finviz target $1.50 = +305% upside IF all catalysts hit
? BEAR CASE (Most Likely)
- Arabia JV CoMira may fail or significantly underdeliver on revenue
- Cash runway only 9 months → dilution risk imminent if JV disappoints
- Primo AI unproven; competitive SaaS diagnostics market; revenue too late anyway
- MTB POC: no guarantee of regulatory approval or commercialization success
- Revenue essentially zero ($145K Q3 = abandoned legacy business)
- Accumulated deficit -$162.3M = likely restructuring/reverse split if turnaround fails
- Micro-cap illiquidity limits ability to raise capital on favorable terms
- Management execution track record negative (post-COVID pivot failed spectacularly)
- TB diagnostics dominated by Cepheid/Danaher, Abbott, Roche dominance
- IF Arabia JV fails by Q2 2026 = bankruptcy/dilution/reverse split highly likely
? Official Sources & SEC Filings (All Verified)
- Co-Diagnostics Investor Relations – SEC Filings
- NASDAQ Official Press Release (Nov 12, 2025)
- PRNewswire – Q3 2025 Earnings (Nov 12, 2025)
- Finviz Elite – Real-Time Stock Screener
- Seeking Alpha Premium – Deep Analysis
- ChartsWatcher – Real-Time Charts
- Medved Trader – Professional Trading Platform
- Co-Diagnostics Official Investor Relations
- Co-Diagnostics Corporate Website
⚠️ DISCLAIMER / RISK DISCLOSURE – EXTREME CAUTION
This report is for informational and educational purposes only and does not constitute financial, investment, or trading advice. The author and Merlintrader are NOT registered investment advisors, brokers, or financial professionals. All information is based on publicly available SEC filings, press releases, and financial data sources.
? SEVERE RISK WARNING: Co-Diagnostics (CODX) is a micro-cap distressed company in SEVERE FINANCIAL DISTRESS with significant bankruptcy and dilution risk. Q3 2025 revenue was only $145K (down 77% YoY). Operating loss $7.0M Q3 2025. Monthly burn rate ~$2.5M. Available liquidity $22.2M extends runway only ~9 months. Arabia Saudita JV partnership is UNPROVEN and may NOT materialize. Primo AI platform is early-stage with NO revenue. Biotech/diagnostics stocks are highly speculative; investors CAN LOSE 100% of their investment. Recent RDO (+$10.8M) extends runway but DOES NOT ELIMINATE fundamental business model failure. This is an EXTREME high-risk, high-reward turnaround speculation ONLY. ONLY for risk-tolerant traders. NOT RECOMMENDED for conservative investors or retirement accounts.
KEY RISKS: Revenue collapse; business model failure (post-COVID); Arabia JV execution uncertainty; Primo AI unproven; regulatory approval uncertainty; TB diagnostics market dominated by larger competitors; dilution/reverse split risk if funding fails; management execution concerns; micro-cap illiquidity; bankruptcy risk if Arabia JV fails by Q2 2026.
DISCLOSURE: Always conduct your own due diligence and consult a licensed financial advisor before making investment decisions. This analysis reflects data as of November 28, 2025. Past performance does not guarantee future results. POSITION SIZE CAREFULLY for penny stocks. Monitor quarterly earnings, Arabia JV progress, and cash runway closely. This stock requires active monitoring and is NOT a buy-and-hold investment.
Data Sources: SEC EDGAR CIK 1378325 (10-Q) | NASDAQ Official Press Release (Nov 12, 2025) | PRNewswire | StockTitan Financial Analysis | Finviz (Nov 28, 2025)
Report Date: November 28, 2025
Last Verified: November 28, 2025, 19:35 CET
Author: Merlintrader.com
Language: English (EN) | Italiano (IT)
© 2025 Merlintrader – All Rights Reserved
Scanner for active traders
Try ChartsWatcher free, then unlock 10% OFF with SAVE10
ChartsWatcher is a real-time scanner for momentum traders: fast movers, unusual volume and rotations — so you can focus on the few tickers that matter right now, instead of watching hundreds of charts.
Start with the free version. When you upgrade, use SAVE10 for 10% OFF your first paid period.
Start free – then use SAVE10
No credit card required to start. Apply SAVE10 when upgrading.
Recommended platform
One platform. All your brokers.
Medved Trader connects multiple brokers in one workspace, with pro charts, hotkeys and fast execution — without changing your broker accounts.
A single cockpit for positions, Level II and multi-broker order routing, built for active day & swing traders.
Get 1 Month Free ➔
Multi-broker workflow + customizable layouts in one platform.
Monica.im – the AI assistant I use every day
If you find value in the work I publish on Merlintrader and want a practical AI assistant for research and writing, you can sign up using this referral link. Click here to try Monica.im and support the site
Find out how I use AI on Merlintrader: AI, retail and Merlintrader
Disclosure: some of the links in the promotional blocks above are affiliate or referral links. If you choose to subscribe or sign up through them, Merlintrader may receive a small commission or benefit at no extra cost to you.
